A new oral GLP-1 medication helped people with type 2 diabetes dramatically improve blood sugar control and lose weight in a major clinical trial. The results suggest that highly effective diabetes ...

EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and ...

Oral GLP-1 medications have the potential to increase access to therapies that can help lower blood sugar and reduce ...

For those scared of needles but who need GLP-1 receptor agonists to help manage their weight, there might be some good news.

A new GLP-1 medication in oral pill form, elecoglipron, could help to significantly reduce blood sugar levels and body weight ...

For Novo Nordisk, the launch of the company’s highly anticipated Wegovy pill at the start of the year—representing the first ...

FDA approvals of Novo Nordisk's oral Wegovy and Eli Lilly's Foundayo have introduced needle-free obesity treatments, offering ...

Lilly's oral GLP-1 orforglipron delivered superior A1C control and weight loss in type 2 diabetes: Our Bureau, Mumbai Thursday, June 11, 2026, 11:00 Hrs [IST] Eli Lilly and Compan ...

The U.S. Food and Drug Administration (FDA) recently approved Eli Lilly and Company’s oral GLP-1 receptor agonist, Foundayo (orforglipron), for chronic weight management in adults with obesity or ...

As real-world studies show high rates of GLP-1 discontinuation and rapid weight regain, new interventions may help patients ...